4 CONCLUSION
In conclusion, this article has given an overview of the effects of sivelestat on ALI/ARDS or ARDS with coagulopathy, both of which are frequently seen in patients with COVID-19. This selective NE inhibitor has not been evaluated for its possible therapeutic effects against SARS-CoV-2 infection and/or COVID-19. Nevertheless, based on its promising beneficial effects in underlying complications of COVID-19, sivelestat could be considered as a promising treatment for the management of ALI/ARDS or coagulopathy in patients with COVID-19. In the end, we think that testing the possible efficacy of this therapeutic modality in this group of patients could help in developing new strategies for combating COVID-19.